DK3296747T3 - Biomarkører for non-alkoholisk fedtleversygdom (NAFLD) og non-alkoholisk steatohepatitis (NASH) og anvendelser deraf - Google Patents

Biomarkører for non-alkoholisk fedtleversygdom (NAFLD) og non-alkoholisk steatohepatitis (NASH) og anvendelser deraf Download PDF

Info

Publication number
DK3296747T3
DK3296747T3 DK17197260.7T DK17197260T DK3296747T3 DK 3296747 T3 DK3296747 T3 DK 3296747T3 DK 17197260 T DK17197260 T DK 17197260T DK 3296747 T3 DK3296747 T3 DK 3296747T3
Authority
DK
Denmark
Prior art keywords
alcoholic
nafld
nash
biomarkers
applications
Prior art date
Application number
DK17197260.7T
Other languages
English (en)
Inventor
Malti Nikrad
Stuart G Field
Stephen Alaric Williams
Original Assignee
Somalogic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somalogic Inc filed Critical Somalogic Inc
Application granted granted Critical
Publication of DK3296747T3 publication Critical patent/DK3296747T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/978Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G01N2333/98Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/08Hepato-biliairy disorders other than hepatitis
    • G01N2800/085Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/60Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK17197260.7T 2013-03-15 2014-03-10 Biomarkører for non-alkoholisk fedtleversygdom (NAFLD) og non-alkoholisk steatohepatitis (NASH) og anvendelser deraf DK3296747T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361787967P 2013-03-15 2013-03-15
EP14717266.2A EP2972386B1 (en) 2013-03-15 2014-03-10 Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof

Publications (1)

Publication Number Publication Date
DK3296747T3 true DK3296747T3 (da) 2020-03-30

Family

ID=50483498

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17197260.7T DK3296747T3 (da) 2013-03-15 2014-03-10 Biomarkører for non-alkoholisk fedtleversygdom (NAFLD) og non-alkoholisk steatohepatitis (NASH) og anvendelser deraf

Country Status (10)

Country Link
US (3) US9612248B2 (da)
EP (3) EP2972386B1 (da)
CN (2) CN108957006B (da)
BR (1) BR122019026188B1 (da)
DK (1) DK3296747T3 (da)
ES (2) ES2773999T3 (da)
HK (1) HK1220251A1 (da)
MX (1) MX360140B (da)
WO (1) WO2014150198A2 (da)
ZA (1) ZA201506441B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2972386B1 (en) * 2013-03-15 2018-01-10 Somalogic, Inc. Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
SG11201707276PA (en) 2015-03-09 2017-10-30 Intekrin Therapeutics Inc Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
WO2016196945A1 (en) * 2015-06-05 2016-12-08 Regulus Therapeutics Inc. Non-alcoholic fatty liver disease biomarkers
EP3414575A1 (en) * 2016-02-08 2018-12-19 Somalogic, Inc. Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
WO2017156310A1 (en) * 2016-03-09 2017-09-14 Molecular Stethoscope, Inc. Methods and systems for detecting tissue conditions
CN107630084A (zh) * 2016-07-18 2018-01-26 昆山德诺瑞尔生物科技有限公司 非酒精性脂肪性肝炎的多基因组合检测试剂盒
JP6893406B2 (ja) * 2016-10-19 2021-06-23 日本化薬株式会社 Nashやnafldの進展度の検査方法及び炎症疾患や癌の検査方法
JP7111322B2 (ja) 2016-12-02 2022-08-02 国立大学法人 東京大学 線維化関連分子に対する抗体およびその医療応用
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy
US20230194536A1 (en) * 2017-11-15 2023-06-22 Beth Israel Deaconess Medical Center, Inc. Markers for the diagnosis and treatment of non-alcoholic steatohepatitis (nash) and advance liver fibrosis
EP3716986A4 (en) * 2017-12-01 2022-02-09 Cornell University NANOPARTICLES AND SUBSETS OF DISTINCT EXOSOMES FOR CANCER DETECTION AND TREATMENT
JP2022505834A (ja) * 2018-10-26 2022-01-14 モレキュラー ステソスコープ, インコーポレイテッド 肝疾患の疾患層別化および関連方法
SG11202108405VA (en) 2019-02-14 2021-08-30 Mirvie Inc Methods and systems for determining a pregnancy-related state of a subject
CN110786834B (zh) * 2019-12-09 2022-04-05 中电健康云科技有限公司 一种基于舌象特征和bmi指数的脂肪肝预测模型
KR20220140727A (ko) * 2020-02-10 2022-10-18 소마로직 오퍼레이팅 컴퍼니, 인코포레이티드 비알코올성 지방간염 (nash) 바이오마커 및 이의 용도
WO2022093757A1 (en) * 2020-10-30 2022-05-05 The General Hospital Corporation Kits, reagents and methods for the assessment of liver diseases
WO2022114887A1 (ko) * 2020-11-27 2022-06-02 국립암센터 통합전사체분석 기반 만성 간질환 진단용 복합마커 및 이의 용도
WO2022258788A1 (en) * 2021-06-09 2022-12-15 Université Catholique de Louvain System and method for determining a risk of having or developing steatohepatitis and/or a complication thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763177A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
JP2763958B2 (ja) 1990-06-11 1998-06-11 ネクスター ファーマスーティカルズ,インコーポレイテッド 核酸リガンド
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US6001577A (en) 1998-06-08 1999-12-14 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US6458539B1 (en) 1993-09-17 2002-10-01 Somalogic, Inc. Photoselection of nucleic acid ligands
US6242246B1 (en) 1997-12-15 2001-06-05 Somalogic, Inc. Nucleic acid ligand diagnostic Biochip
EP1656155A2 (en) * 2003-06-02 2006-05-17 Ohio University Use of genes differentially expressed during aging of liver for treatment and diagnosis
WO2007133586A2 (en) 2006-05-08 2007-11-22 Tethys Bioscience, Inc. Systems and methods for developing diagnostic tests based on biomarker information from legacy clinical sample sets
US7855054B2 (en) 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
WO2008156662A1 (en) * 2007-06-14 2008-12-24 George Mason Intellectual Properties, Inc. Methods of diagnosing non-alcoholic steatohepatitis (nash)
AU2008275917B2 (en) 2007-07-17 2014-08-21 Somalogic Operating Co., Inc. Multiplexed analyses of test samples
EP2313782B1 (en) 2008-07-03 2012-08-29 One Way Liver Genomics, S.L. Proteomic fingerprint for the diagnosis of non-alcoholic steatohepatitis (nash) and/or steatosis
US20100124548A1 (en) * 2008-10-29 2010-05-20 University Of Oulu Pharmaceutical product
WO2011054893A2 (en) * 2009-11-05 2011-05-12 Novartis Ag Biomarkers predictive of progression of fibrosis
CN104777313B (zh) 2010-07-09 2017-09-26 私募蛋白质体公司 肺癌生物标记及其用途
WO2012047618A2 (en) 2010-09-27 2012-04-12 Somalogic, Inc. Mesothelioma biomarkers and uses thereof
CN104812913B (zh) * 2012-11-07 2019-03-15 私募蛋白质体公司 慢性阻塞性肺疾病(copd)生物标记及其用途
EP2972386B1 (en) * 2013-03-15 2018-01-10 Somalogic, Inc. Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof

Also Published As

Publication number Publication date
EP3660512A1 (en) 2020-06-03
US9612248B2 (en) 2017-04-04
CN105143887B (zh) 2018-08-28
ES2773999T3 (es) 2020-07-16
ZA201506441B (en) 2019-07-31
US9945875B2 (en) 2018-04-17
BR122019026188A8 (pt) 2022-10-18
EP3296747B1 (en) 2020-01-08
ES2662108T3 (es) 2018-04-05
WO2014150198A3 (en) 2014-12-18
US20180259537A1 (en) 2018-09-13
MX2015011756A (es) 2016-01-14
CN105143887A (zh) 2015-12-09
HK1220251A1 (zh) 2017-04-28
MX360140B (es) 2018-10-24
US20170227550A1 (en) 2017-08-10
US10359435B2 (en) 2019-07-23
BR122019026188A2 (da) 2017-07-18
BR112015021992A8 (pt) 2019-12-03
WO2014150198A2 (en) 2014-09-25
US20140303018A1 (en) 2014-10-09
EP2972386A2 (en) 2016-01-20
EP3660512B1 (en) 2024-07-24
BR112015021992A2 (pt) 2017-07-18
EP3296747A1 (en) 2018-03-21
CN108957006B (zh) 2021-07-27
EP2972386B1 (en) 2018-01-10
CN108957006A (zh) 2018-12-07
BR122019026188B1 (pt) 2024-01-02

Similar Documents

Publication Publication Date Title
DK3296747T3 (da) Biomarkører for non-alkoholisk fedtleversygdom (NAFLD) og non-alkoholisk steatohepatitis (NASH) og anvendelser deraf
DK3458479T3 (da) Anti-b7-h3-antistoffer og antistof-lægemiddelkonjugater
DK2970460T3 (da) Anti-IL-33-antistoffer og anvendelser deraf
DK3443009T3 (da) Anti-tim-3-antistoffer og sammensætninger
CL2016001477A1 (es) Anticuerpos e inmunoconjugados anti-cd33
DK3008168T3 (da) Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
DK2968552T3 (da) Targeteringsmiddel-antistofkonjugater og anvendelser deraf
DK3307274T3 (da) Anti-cd123-antistoffer og konjugater deraf
DK2958944T3 (da) Anti-dll3-antistof-pbd-konjugater og anvendelser deraf
DK3316909T3 (da) Anti-ntb-a-antistoffer og relaterede sammensætninger og fremgangsmåder
IL240183A (en) Non-Alcoholic Obesity Preparation (nafld)
DK3019533T3 (da) Dobbeltspiraliserede immunoglobulinfusionproteiner og sammensætninger deraf
DK3026062T3 (da) Anti-pd-1-antistof og anvendelse deraf
DK2943078T3 (da) Fremgangsmåder og sammensætninger til føde- og drikkevarer
DK2914291T3 (da) Anti-komplement-c1s-antistoffer og anvendelser deraf
DK3004162T3 (da) Anti-væg-teichoin-antistoffer og konjugater
DK3480215T3 (da) Anti-HER2-antistof og konjugat deraf
DK3079719T3 (da) ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf
DK2953971T3 (da) Il-11r-bindende proteiner og anvendelser deraf
DK3063144T3 (da) Antiparasitære og pesticid-isoxazolinforbindelser
DK3003117T3 (da) Videolaryngoskop og laryngoskopindføringsdel
DK3077467T3 (da) Sikkativsammensætning og anvendelse deraf
DK3065771T3 (da) Fremgangsmåder og sammensætninger til vedvarende immunterapi
DK3030549T3 (da) Pyridazinonforbindelser og anvendelser deraf
DK2964767T3 (da) Toksingener og fremgangsmåder til anvendelse deraf